Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Core Insights - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing immunology-based therapies [3] - The company will present at the Guggenheim SMID Cap Biotech Conference on February 5, 2025, at 3:00 p.m. ET [1] Company Overview - Zenas aims to lead in the development of transformative therapies for autoimmune diseases, leveraging an experienced leadership team and a disciplined approach to product candidate acquisition [3] - The lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, designed to inhibit the activity of B cells implicated in autoimmune diseases without depleting them [3] - Obexelimab's mechanism of action and self-administered subcutaneous injection regimen may effectively address the role of B cells in chronic autoimmune diseases [3]